Information about the organizers, sponsors and partners


Tel.: + 33 1 75 44 69 42


About ETPN

Created in 2005, the European Technology Platform on Nanomedicine (ETPN), an initiative led by industry and set up together with the European Commission, is addressing the application of nanotechnology to achieve breakthroughs in healthcare. Its mission consists in building, shaping and supporting the European ecosystem of Nanomedicine. In 2015, the ETPN became an independent international Association under the French law 1901, with its Secretariat and headquarters located in Paris, France.

ETPN has developed solid and effective tools under the umbrella of the Nanomedicine Translation Hub aiming to select and help the development of the best innovative projects in Nanomedicine toward the clinic.


Enabling NAnomedicine TRANSlation, aCoordination and Support Action funded by the European Commission, has beenbuilt to help the translation of innovative projects related to Nanomedicine tosuccessfully go through the different stages of development from the idea tothe patients and also improve global knowledge on Nanomedicine. ENATRANS is ledby a consortium of 7 partners belonging to the European Technology Platform forNanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris,France), Gesellschaft fur Bioanalytik Muenster e.V. (Muenster, Germany),Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS(Milan, Italy), TecMinho (Braga, Portugal) and VDI/VDE-IT (Berlin, Germany).



EBD Group is the leading partnering firm for the global life science industry. 

Since 1993, biotech, pharma and medical device and related life science companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. 

EBD Group’s conferences are run with the support of leading corporations and international trade associations, include BIO-Europe®, BIO-Europe Spring®, BioPharm America™, EuroMedtech™, BioEquity Europe, ChinaBio® Partnering Forum, Medtech Partnering Forum, Partnering for Global Impact®, and Biotech Showcase™. EBD Group’s sophisticated web-based partnering service, partneringONE®, also powers numerous third-party events, and partnering360® is the open online community of life science deal makersthat enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.


Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

The Company started in 2016 a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarters are based in Paris, France, with an affiliate in Cambridge, Massachusetts.